Poseida Therapeutics, Inc.

NasdaqGS:PSTX Rapport sur les actions

Capitalisation boursière : US$300.2m

Poseida Therapeutics Gestion

Gestion contrôle des critères 3/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Kristin Yarema

Directeur général

US$2.6m

Rémunération totale

Pourcentage du salaire du PDG14.7%
Durée du mandat du directeur généralless than a year
Propriété du PDGn/a
Durée moyenne d'occupation des postes de direction2.8yrs
Durée moyenne du mandat des membres du conseil d'administration3.5yrs

Mises à jour récentes de la gestion

Recent updates

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%

Oct 19
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 30%

Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement

Sep 30

Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024

Sep 09

Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop

Aug 28
Lacklustre Performance Is Driving Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) 29% Price Drop

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

May 21
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Apr 09
Investors Don't See Light At End Of Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Tunnel And Push Stock Down 27%

Poseida: April 2024 Data Could Shed Light On Differentiated CAR-T Advancement

Mar 17

Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Jan 24
Poseida Therapeutics (NASDAQ:PSTX) Has Debt But No Earnings; Should You Worry?

Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

Dec 18
Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Price Boosted 43% But Its Business Prospects Need A Lift Too

New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Aug 13
New Forecasts: Here's What Analysts Think The Future Holds For Poseida Therapeutics, Inc. (NASDAQ:PSTX)

Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Apr 17
Little Excitement Around Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Revenues As Shares Take 44% Pounding

Poseida Therapeutics: Collaboration Agreement With Roche Helps Validate Genetic Engineering Tech

Sep 04

Poseida Therapeutics GAAP EPS of -$0.69 beats by $0.08, revenue of $2.7M beats by $1.77M

Aug 11

Poseida jumps 56% as Roche eyes CAR-T drugs in deal worth up to $6B

Aug 03

Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

May 15
Earnings Release: Here's Why Analysts Cut Their Poseida Therapeutics, Inc. (NASDAQ:PSTX) Price Target To US$16.25

Poseida Therapeutics: Genome Engineering For Safer Cell Therapies

Oct 30

What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Mar 19
What Type Of Shareholders Make Up Poseida Therapeutics, Inc.'s (NASDAQ:PSTX) Share Registry?

Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Jan 25
Did Poseida Therapeutics, Inc. (NASDAQ:PSTX) Insiders Buy Up More Shares?

Poseida Therapeutics (PSTX) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 09

FDA lifts clinical hold on Poseida's prostate cancer cell therapy study

Nov 02

Analyse de la rémunération des PDG

Comment la rémunération de Kristin Yarema a-t-elle évolué par rapport aux bénéfices de Poseida Therapeutics?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

-US$61m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$109m

Dec 31 2023US$3mUS$381k

-US$123m

Rémunération vs marché: La rémunération totale de Kristin ($USD 2.58M ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 2.34M ).

Rémunération et revenus: Données insuffisantes pour comparer la rémunération de Kristin avec les performances de l'entreprise.


PDG

Kristin Yarema (53 yo)

less than a year

Titularisation

US$2,581,106

Compensation

Dr. Kristin Yarema Ph.D. is President & CEO of Poseida Therapeutics, Inc. from January 01, 2024 and serves as its Director since January 2024. Dr. Yarema, was the Chief Commercial Officer and Senior Vice P...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Mark Gergen
Executive Chairman of the Board6.8yrsUS$3.82m0.15%
$ 448.2k
Kristin Yarema
Presidentless than a yearUS$2.58mpas de données
Johanna Mylet
Chief Financial Officer4.3yrspas de données0.073%
$ 218.6k
Loren Wagner
Chief Operations Officer2.8yrspas de donnéespas de données
Kristin Martin
Chief People & Administration Officer5.8yrspas de donnéespas de données
Alexander Chapman
Senior VP of Investor Relations & Corporate Communicationsless than a yearpas de donnéespas de données
Harry Leonhardt
General Counsel4.3yrsUS$978.34k0.040%
$ 121.1k
Devon Shedlock
Chief Scientific Officer of Cell Therapy4.8yrspas de donnéespas de données
Lisa Portale
Senior Vice President of Regulatory Affairs3.1yrspas de donnéespas de données
Jeffrey W. Winkelman
Senior VP & Chief Patent Counsel2.8yrspas de donnéespas de données
Karen Basbaum
Senior Vice President of Business Development2.8yrspas de donnéespas de données
Syed Rizvi
Chief Medical Officerless than a yearpas de donnéespas de données

2.8yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Gestion expérimentée: L'équipe de direction de PSTX est considérée comme expérimentée (ancienneté moyenne 2.8 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Mark Gergen
Executive Chairman of the Board6.8yrsUS$3.82m0.15%
$ 448.2k
Kristin Yarema
Presidentless than a yearUS$2.58mpas de données
John Schmid
Lead Independent Director6.3yrsUS$175.11k0.040%
$ 121.0k
Carl June
Chairman of Cell Therapy Scientific Advisory Board3.7yrspas de donnéespas de données
George Church
Chairman of Gene Therapy Scientific Advisory Board2.3yrspas de donnéespas de données
Marcea Lloyd
Independent Director5.8yrsUS$149.11k0.051%
$ 151.8k
Cynthia Collins
Independent Director3.3yrsUS$155.28k0.040%
$ 121.0k
Charles Baum
Independent Director2.5yrsUS$150.28k0.047%
$ 141.2k
Luke Corning
Independent Director3.9yrsUS$140.11k0.040%
$ 121.0k
Luca Gattinoni
Member of Scientific Advisory Board3.5yrspas de donnéespas de données
Christine Brown
Member of Scientific Advisory Board3.5yrspas de donnéespas de données
Jan Joseph Melenhorst
Member of Scientific Advisory Board3.5yrspas de donnéespas de données

3.5yrs

Durée moyenne de l'emploi

66yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de PSTX sont considérés comme expérimentés (ancienneté moyenne 3.5 ans).